Charles River Laboratories Intl. Inc vs NetFlix Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $303.09 (market cap $14.23B), while NetFlix Inc trades at $70.6 (market cap $298.01B). The key difference: NetFlix Inc is far larger — about 20.9× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, NetFlix Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and NetFlix Inc for 125 Days on average.
| CRL | NFLX | |
|---|---|---|
Market Cap | $14.23B | $298.01B |
Volume | 1,176,885 | 45,805,108 |
Sector | Health | Media |
52-Week High | $310.77 | $124.13 |
52-Week Low | $149.93 | $67.06 |
Typical Hold Time | 33 Days | 125 Days |
Enterprise Value | $17.06B | $303.19B |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Netflix trades at $69.70, up 1.47% today, with strong fundamentals including 28.2% net margin and 49.5% ROE. The stock shows bearish technical signals despite beating earnings expectations for three consecutive quarters. Recent news highlights Netflix's live sports strategy and content investments, while analyst consensus remains bullish with a $89.78 price target representing 29% upside potential.
Netflix presents a compelling growth story with expanding profitability and strategic content investments, though technical weakness and competitive pressures warrant caution. The company's strong cash flow generation and institutional interest support long-term upside, but investors should monitor execution risks in the evolving streaming landscape.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →